Eloxx Pharmaceuticals (NASDAQ:ELOX) Trading Down 8.1%

Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOXGet Rating) shares traded down 8.1% during trading on Friday . The stock traded as low as $2.80 and last traded at $2.99. 21,145 shares were traded during trading, a decline of 87% from the average session volume of 160,426 shares. The stock had previously closed at $3.25.

Analyst Upgrades and Downgrades

Separately, Oppenheimer dropped their price objective on Eloxx Pharmaceuticals from $120.00 to $50.00 in a research note on Thursday, January 5th.

Eloxx Pharmaceuticals Price Performance

The business has a 50 day moving average price of $3.83 and a two-hundred day moving average price of $1.81. The stock has a market cap of $6.48 million, a PE ratio of -0.16 and a beta of 2.64. The company has a debt-to-equity ratio of 6.14, a quick ratio of 1.18 and a current ratio of 1.18.

Hedge Funds Weigh In On Eloxx Pharmaceuticals

An institutional investor recently raised its position in Eloxx Pharmaceuticals stock. Bank of America Corp DE boosted its position in Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOXGet Rating) by 238.0% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 58,213 shares of the company’s stock after acquiring an additional 40,990 shares during the quarter. Bank of America Corp DE owned 0.07% of Eloxx Pharmaceuticals worth $32,000 as of its most recent filing with the Securities & Exchange Commission.

Eloxx Pharmaceuticals Company Profile

(Get Rating)

Eloxx Pharmaceuticals, Inc engages in the development of novel ribonucleic acid-modulating drug candidates. The firm focuses on the the formulation of medicines to treat rare and ultra-rare premature stop codon diseases. Its lead product candidate is ELX-02, a small molecule drug designed to restore production of full-length functional proteins.

Featured Stories

Receive News & Ratings for Eloxx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eloxx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.